Skip to content

Depression: all studies

Page 149 of 1,034: studies 1,481 to 1,490 of 10,336, newest first. Back to the depression overview

Research

Efficacy of esketamine for the treatment of postpartum depression and pain control following cesarean section: a randomized, double-blind, controlled clinical trial

BMC Anesthesiology February 6, 2024 Shurong Li, Zhifang Zhuo, Renwei Li et al.

Background Postpartum depression (PPD) following a cesarean delivery is a frequently seen complication. Despite the prophylactic effects of ketamine, the impact of esketamine on PPD in women undergoing cesarean section remains uncertain. This study aimed to assess the effectiveness of esketamine as an adjunct to patient-controlled intravenous analgesia (PCIA) in preventing PPD in women...

Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study

Scientific Reports February 5, 2024 Alistair Niemeijer, Erwin Krediet, Jeanine Kamphuis et al. 50 citations

Abstract Psilocybin is the most researched classic psychedelic for Treatment-Resistant Depression (TRD). While optimizing set and setting are considered essential for efficacy and safety, patient perspectives on these aspects have rarely been investigated. To address this knowledge gap, the current paper explored the experiences of 11 TRD patients (8 women, 3 men) participating in a...

Anhedonia in bipolar depression treated with ketamine

Bipolar Disorders February 4, 2024 Alina Wilkowska, Mariusz S. Wiglusz, Aleksandra Arciszewska et al. 17 citations

BACKGROUND: Bipolar depression is the major cause of morbidity in patients with bipolar disorder. It affects psychosocial functioning and markedly impairs occupational productivity. Anhedonia is one of the most debilitating symptoms of depression contributing to treatment resistance. It correlates with suicidality, low quality of life, social withdrawal, and poor treatment response. Currently,...

DOI: 10.1111/bdi.13409 (opens in new tab) Ketamine Anhedonia Depression economics Bipolar disorder +3

Anti-inflammatory effects of ketamine in the treatment-resistant depression: a narrative review

Farmacja Polska February 3, 2024 Marta Jóźwiak-Bębenista, Paulina Sokołowska, Edward Kowalczyk et al.

Przedmiot badań. U części pacjentów z depresją szczególnie nie odpowiadających na leczenie standardowymi lekami przeciwdepresyjnymi lub z myślami bądź próbami samobójczymi, stan zapalny jako źródło cytokin, przyczynia się do braku odpowiedzi na zastosowane terapie. Szansą dla takich osób jest terapia przy pomocy ketaminy. S-ketamina to szybko działający lek przeciwdepresyjny o wysokiej...

Latent Profile Analysis of the Five Facet Mindfulness Questionnaire (FFMQ) Subscales in a Naturalistic Sample of Patients with Past or Present Major Depression: A Replication and Extension Study

Mindfulness February 1, 2024 Jelle Lubbers, Philip Spinhoven, Mira B. Cladder-Micus et al.

Abstract Objectives Mindfulness is a multifaceted concept which might be best captured by person-centered profiles rather than by variable-centered assessment of its subcomponents. Patients with different mindfulness profiles may vary in mental health status and might experience differential clinical outcomes of Mindfulness-Based Cognitive Therapy (MBCT). We therefore aimed to assess the...

Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis

Frontiers in Psychiatry February 1, 2024 Alessandro Rodolico, Pierfelice Cutrufelli, Antonio Di Francesco et al. 28 citations

Background Unipolar and bipolar depression present treatment challenges, with patients sometimes showing limited or no response to standard medications. Ketamine and its enantiomer, esketamine, offer promising alternative treatments that can quickly relieve suicidal thoughts. This Overview of Reviews (OoR) analyzed and synthesized systematic reviews (SRs) with meta-analysis on randomized...

The efficacy of mindfulness apps on symptoms of depression and anxiety: An updated meta-analysis of randomized controlled trials.

Clinical Psychology Review February 1, 2024 Jake Linardon, Mariel Messer, Simon B. Goldberg et al. 61 citations

Mindfulness apps have become popular tools for addressing symptoms of depression and anxiety. Since the publication of earlier meta-analyses evaluating the efficacy of mindfulness apps for depression and anxiety symptoms, over 20 randomized controlled trials (RCTs) have been conducted. There is a need for an updated meta-analysis that quantifies the effects of mindfulness apps on these symptoms...

The effect of a mindfulness-based intervention on stress overload, depression, and mindfulness among nurses: A randomized controlled trial.

Worldviews on Evidence-Based Nursing February 1, 2024 Aida M. Alfurjani, Mohammed Munther Al-Hammouri, Jehad A. Rababah et al. 12 citations

Nurses experience various health-related issues due to the nature of their work. This study aimed to examine the effect of a mindfulness-based intervention on stress overload, depression and mindfulness among nurses. A secondary objective was to examine the role of the setting (i.e., in and out of the hospital as a natural setting) on mindfulness-based intervention effectiveness. A randomized...

DOI: 10.1111/wvn.12695 (opens in new tab) Full text (opens in new tab) Depression Mindfulness-based intervention Nurses Stress overload

Ensuring the affordable becomes accessible-lessons from ketamine, a new treatment for severe depression.

Australian & New Zealand Journal of Psychiatry February 1, 2024 Anthony Rodgers, Dilara Bahceci, Christopher G. Davey et al. 8 citations

In this paper, the case study of ketamine as a new treatment for severe depression is used to outline the challenges of repurposing established medicines and we suggest potential solutions. The antidepressant effects of generic racemic ketamine were identified over 20 years ago, but there were insufficient incentives for commercial entities to pursue its registration, or support for...

Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.

Cureus February 1, 2024 Suneeta Kumari, Hassan A Chaudhry, Adam Sagot et al. 13 citations

The expansive spectrum of major depressive disorder (MDD) continues to pose challenges for psychiatrists to treat effectively. Oral antidepressant (OAD) medications that alter monoamine neurotransmitters, mainly selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs), have been the mainstay of therapy for decades. Although these drugs have been...

DOI: 10.7759/cureus.53987 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression FDA Approval Nmda receptor antagonist Placebo controlled trials +6